The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database
Open accessAbstract
AIM: To review special safety topics associated with sildenafil and to document the tolerability of 50- and 100-mg doses, overall and by age, in men with erectile dysfunction (ED). METHODS: Data were collated from 67 double-blind placebo-controlled (DBPC) trials (> 14,000 men) conducted by the manufacturer and from the manufacturer's postmarketing safety database (39,277 patients). The DBPC data were stratified by dose, starting dose and age (> or = 65 and > or = 75 years). Special safety topics included cardiovascular risk, priapism, non-arteritic anterior ischaemic optic neuropathy (NAION), impaired renal and hepatic function, drug interactions (i.e. nitrates, cytochrome P3A4 inhibitors, other ED therapies and alpha-blockers) and incorrect use. RESULTS: Sildenafil was well tolerated at a dose of 50 or 100 mg in men with ED, overall, in those aged > or = 65 years, and in those aged > or = 75 years. Analyses of the databases did not reveal any causal link between sildenafil and cardiovascular events, or any new safety risks relating to cardiovascular events, priapism, NAION, hearing loss or drug interactions. In the small number of men with moderate impairment of renal function or hepatic function who were treated with sildenafil in DBPC trials, the safety profile was similar to that in men with no impairment of renal or hepatic function. Overdose with sildenafil was rare in the ED population. No new safety issues, emerging trends or adverse reactions were identified in conjunction with overdose, dependence, abuse or misuse. CONCLUSION: This collated review confirms generally the good tolerability and established safety profile of sildenafil 50 and 100 mg in men with ED and reveals no new safety issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinlay, J. B. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)34871-1 · Cited by 5,074
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
Prevalence and Risk Factors for Erectile Dysfunction in 2869 Men Using a Validated Questionnaire
PONHOLZER, A., TEMML, C., MOCK, K., MARSZALEK, M., OBERMAYR, R., & MADERSBACHER, S. (2005) · European Urology · doi:10.1016/j.eururo.2004.08.017 · Cited by 361
Recreational Use and Misuse of Phosphodiesterase 5 Inhibitors
Smith, K. M., & Romanelli, F. (2005) · Journal of the American Pharmacists Association · doi:10.1331/1544345052843165 · Cited by 103
Cited by
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation
Hatzimouratidis, K., Amar, E., Eardley, I., Giuliano, F., Hatzichristou, D., Montorsi, F., Vardi, Y., & Wespes, E. (2010) · European Urology · doi:10.1016/j.eururo.2010.02.020 · Cited by 1,223
Self-citationYafi, F. A., Jenkins, L., Albersen, M., Corona, G., Isidori, A. M., Goldfarb, S., Maggi, M., Nelson, C. J., Parish, S., Salonia, A., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.3 · Cited by 853
Nehra, A., Jackson, G., Miner, M., Billups, K. L., Burnett, A. L., Buvat, J., Carson, C. C., Cunningham, G. R., Ganz, P., Goldstein, I., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.06.015 · Cited by 471
Self-citationMechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction
Andersson, K.-E. (2011) · Pharmacological Reviews · doi:10.1124/pr.111.004515 · Cited by 392
Evaluation and Management of Erectile Dysfunction
Burnett, A. L. (2012) · Campbell-Walsh Urology · doi:10.1016/b978-1-4160-6911-9.00024-4 · Cited by 28
Metadata
- Authors
- Giuliano, F., Jackson, G., Montorsi, F., Martin-Morales, A., & Raillard, P.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2009-11-09
- Volume
- 64
- Issue
- 2
- Pages
- 240-255
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W1491683555
- Cited by
- 164
- References
- 5
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. https://app.cochat.ai/papers/10.1111/j.1742-1241.2009.02254.x
- The paper
- Giuliano, F., Jackson, G., Montorsi, F., Martin-Morales, A., & Raillard, P. (2009). Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2009.02254.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.